Stifel Maintains Buy Rating, Raises PT for uniQure to $65 from $30.

Stifel Maintains Buy Rating, Raises PT for uniQure to $65 from $30.

Stifel has reiterated its Buy rating on uniQure BV (NASDAQ: QURE), while raising its price target to $65 from $30. The update comes following the release of three-year data for uniQure's AMT-130 treatment in Huntington’s Disease. The stock has shown remarkable resilience with a 165% return over the past year uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data^[1].

The three-year data exceeded expectations, showing a 75% disease-slowing effect on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) compared to natural history, with statistical significance (p=0.003). The treatment also demonstrated a statistically significant benefit on Total Functional Capacity (TFC) with p=0.033, which Stifel noted was an upside surprise that could be important to FDA approval considerations uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data^[1].

Stifel believes these results strengthen uniQure’s prospects for accelerated FDA approval, with the company on track for a Biologics License Application (BLA) submission in the first quarter of 2026. However, the firm acknowledged some limitations including small sample size and reliance on natural history comparison uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data^[1].

In other recent news, uniQure N.V. has secured a $175 million non-dilutive senior secured term loan facility with Hercules Capital. This agreement enhances uniQure’s financial flexibility, particularly for the potential commercial launch of its gene therapy, AMT-130, aimed at treating Huntington’s disease uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data^[1].

Analysts from Cantor Fitzgerald, Mizuho, and H.C. Wainwright have also expressed positive sentiments about uniQure. Cantor Fitzgerald has reiterated an Overweight rating on uniQure, with a price target of $47.00, citing the potential of AMT-130. Mizuho maintains its Outperform rating and a $30.00 price target, viewing the recent stock price drop as a buying opportunity. H.C. Wainwright continues to support uniQure with a Buy rating and a $70.00 price target, following promising initial Phase 1/2a data for its Fabry disease gene therapy, AMT-191 uniQure stock rating reiterated at Buy by Stifel on strong Huntington’s data^[1].

These developments underscore uniQure’s ongoing efforts in advancing its therapeutic pipeline, which could potentially lead to significant market opportunities.